Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Gemcitabine/Cisplatin + PD-1/PD-L1 Antibody in Advanced ICC
NCT06567600Phase 2Not yet recruiting
- Sponsor
- The Third Affiliated Hospital of Sun Yat-sen University
- Start
- Sep 2024
- Primary completion
- Dec 2027
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, durvalumab in intrahepatic cholangiocarcinoma (ICC), sponsored by The Third Affiliated Hospital of Sun Yat-sen University. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
pembrolizumabdurvalumab
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT06567600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06567600.